Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines

Inclusion Criteria: * Newly diagnosed DIPG Patients without progressive disease * Aged between 3 and 18 yo Lansky scale \>50 (Karnofsky for patients aged more than 16 yr) * Life expectancy \> 8 weeks * Preserved bone marrow function Normal hepatic and renal function Exclusion Criteria: * Impossibility to perform aphaeresis * Patient participation of other experimental study within the last 3 months * Patient under antitumor treatment in the last 4 weeks * Co-morbidity that does not allow the study treatment * Patients requiring \> 2mg/day of dexamethasone treatment Corticoid-dependent patients * Patients under uncontrolled infection * Positive serologies of HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV)